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Background: Health technology assessment and healthcare decision-making are based on multiple criteria and
evidence, and heterogeneous opinions of participating stakeholders. Multi-criteria decision analysis (MCDA) offers
a potential framework to systematize this process and take different perspectives into account. The objectives of
this study were to explore perspectives and preferences across German stakeholders when appraising healthcare
interventions, using multi-criteria assessment of a heart pulmonary sensor as a case study.
Methods: An online survey of 100 German healthcare stakeholders was conducted using a comprehensive
MCDA framework (EVIDEM V2.2). Participants were asked to provide i) relative weights for each criterion of the
framework; ii) performance scores for a health pulmonary sensor, based on available data synthesized for each
criterion; and iii) qualitative feedback on the consideration of contextual criteria. Normalized weights and scores
were combined using a linear model to calculate a value estimate across different stakeholders. Differences
across types of stakeholders were explored.
Results: The survey was completed by 54 participants. The most important criteria were efficacy, patient reported
outcomes, disease severity, safety, and quality of evidence (relative weight >0.075 each). Compared to all
participants, policymakers gave more weight to budget impact and quality of evidence. The quantitative appraisal
of a pulmonary heart sensor revealed differences in scoring performance of this intervention at the criteria level
between stakeholder groups. The highest value estimate of the sensor reached 0.68 (on a scale of 0 to 1, 1
representing maximum value) for industry representatives and the lowest value of 0.40 was reported for
policymakers, compared to 0.48 for all participants. Participants indicated that most qualitative criteria should be
considered and their impact on the quantitative appraisal was captured transparently.
Conclusions: The study identified important variations in perspectives across German stakeholders when appraising a
healthcare intervention and revealed that MCDA can demonstrate the value of a specified technology for all
participating stakeholders. Better understanding of these differences at the criteria level, in particular between
policymakers and industry representatives, is important to focus innovation aligned with patient health and healthcare
system values and constraints.
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Health technology assessment (HTA) is defined by the
European Network for HTA as a “multidisciplinary
process that summarizes information about the medical,
social, economic and ethical issues related to the use of a
health technology in a systematic, transparent, unbiased,
robust manner. Its aim is to inform the formulation of
safe, effective, health policies that are patient focused
and seek to achieve best value” [1]. Accordingly, HTA is
an essential tool for health policy decision-making as it
assesses the available evidence about new health
technologies.
HTA and policy decisions are usually complex due to
the multiple aspects considered and the extensive
amount of evidence. Frequent gaps in the evidence and
associated uncertainty also contribute to the challenges
faced by decision makers. Complex interventions com-
plicate this problem further. The implementation aspects
of complex health interventions are an essential link to
the desired health outcomes [2,3]. In turn, the success or
failure in improving health outcomes is not always
attributed to the complex intervention itself but to
context- and implementation-related issues. In order to
achieve a comprehensive assessment of complex tech-
nologies, a variety of different issues have to be assessed
such as effectiveness, ethical, context, and implementa-
tion issues [2]. However, the different aspects of HTA
are not systematically taken into account for health
policymaking. The results are mainly presented side-by-
side and decision-makers are struggling to evaluate
contradicting outcomes of complex HTA (e.g., better
medical outcome but worse social outcome) [4].
In addition, the current approaches in HTA and
healthcare decision-making have some limitations
regarding the integration of the diversity of stakeholders’
preferences and perspectives in their processes. On the
one hand, patient and public involvement is gaining
more and more attention from health policymakers [5].
On the other hand, health economic tools are not able
to identify and address the multiple voices of healthcare
stakeholders [6]. Daniels’ ethical framework of ‘account-
ability for reasonableness’ provides the foundation for
fair evaluation of healthcare interventions and fair
decision-making [7]. According to this framework, all
reasons and criteria for funding healthcare have to be
accessible to all stakeholders. The reasons must be based
on principles that ‘fair-minded’ people would agree
upon. The criteria should reflect a society’s value [8].
These issues are all of a fundamental democratic nature
and thus constitute the basis for acceptability of deci-
sions. An optimal scenario would be to have a societal
consensus on a collective solution for society and all
important stakeholders to address rationing issues and
the decision-making process associated with these. Thiscould be achieved by engaging all stakeholders and
ensure consideration of all stakeholders perspectives,
preferences, and constraints.
Comprehensive multi-criteria decision analysis (MCDA)
provides a tool in this direction. Its methodological basis
enables the exploration of stakeholders’ preferences and
perspectives and to explicitly structure the broad range of
criteria on which real life evaluations and decisions are
based [9]. MCDA provides insights into the rationale be-
hind decision-making processes [10]. The MCDA process
is democratic by nature and consists of several steps.
Firstly, the decision problem needs to be defined and
structured, i.e., the identification of valuable healthcare in-
terventions from a holistic perspective. Secondly, a set of
mutually independent criteria is defined and weighted
based on their importance to individual stakeholders in-
volved in the process. Thirdly, the appraised interventions
are assigned scores based on their performance for each
criterion; this is performed based on data available, hence
the importance of aligning data development with deci-
sion criteria. Finally, a value estimate is calculated by com-
bining weights and scores. A number of MCDA methods
are available [11], with various degrees of complexity, in-
cluding direct methods, such as 5- or 10-point weighting
scales (Kepner Tregoe [12]), ranking, point allocation,
analytic hierarchy process (AHP) [13], or indirect methods
such discrete choice experiments (DCEs) [14-17]. DCEs
have been successfully employed when the number of out-
comes is small, while AHP is cognitively demanding for
participants. The hierarchical structure of AHP in addition
to the high number of evaluated alternatives can appear
too complex for participants [18]. In DCE studies, the
number of criteria levels is an important issue. Scoring of
criteria with two levels is mostly not sufficient to illustrate
the real world. However, the addition of criteria levels
would have increased the complexity of discrete choices
for respondents [14,17,19,20]. For this study, we selected
an existing, open source, comprehensive MCDA frame-
work, developed collaboratively through input of various
stakeholders and which meets the methodological require-
ments of completeness, redundancy, and mutual inde-
pendence [21-23]. This pragmatic framework, tested,
adapted, and used by several HTA agencies [24-26], pro-
vides several weight elicitation methods (www.evidem.org),
and includes a set of relevant criteria to explore stake-
holders perspectives and preferences regarding evaluation
and decision making for healthcare interventions. The
framework consists of a core quantitative MCDA model
and a qualitative contextual tool, with a comprehensive
range of criteria and sub-criteria, which allows for adapta-
tion to context.
The objectives of this study were to explore perspectives
and preferences, in the German context and across differ-
ent types of stakeholders, when appraising healthcare
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pulmonary sensor as a case study.
Methodology
Study design
The EVIDEM (EVIdence based Decision-Making)
framework, designed to assess interventions in health-
care using quantitative and qualitative decision criteria,
was selected. This established framework proposes a
comprehensive range of criteria fulfilling the methodo-
logical requirements of MCDA models. Additionally, we
provided synthesized data on the heart sensor for each
of these criteria to make the online survey feasible and
to allow exploration of perspectives from a broad range
of stakeholders. The framework, which includes norma-
tive (i.e., what we should do?) and feasibility (what can
be done?) criteria, was adapted for this study in the
German context including its translation. The EVIDEM
core model used in this study consisted of 14 universal,
quantitative criteria, while the contextual tool included 8
qualitative criteria. A definition of all criteria and scales
used in the survey is provided in the Additional file 1:
Table S1. Stakeholders across the German healthcare
continuum (developers, health policymakers, healthcare
professionals, citizens, and researchers) were invited to
participate in an online survey about the assessment of a
pulmonary heart sensor.
In the first part of the survey, individual perspectives
on what matters most in HTA, i.e., which criteria con-
tribute the most to the value of healthcare interventions,
was captured by weight elicitation independently of the
intervention. Participants were asked to provide relative
weights for each criterion of the MCDA core model
from their individual perspective, but in the context of
coverage decision for healthcare interventions in general.
For this survey, we selected a 5-point weighting scale.
Participants provided a relative weight for each decision
criterion of the quantitative core model, using a 5-point
scale (1 = lowest relative importance, 5 = highest relative
importance). They were also asked whether the context-
ual criteria should be considered for coverage decisions
(Additional file 1: Table S1). For qualitative criteria of
the contextual tool, participants indicated whether each
criterion should never, rarely, sometimes, often, or al-
ways be included in decision-making processes. Detailed
information with a definition of each criterion was pro-
vided to participants (Additional file 1: Table S1).
In the second part of the survey, in order to explore
perspectives and differences on how an intervention is
evaluated with regard to its performance for each criter-
ion, participants were asked to appraise a pulmonary
heart sensor using an MCDA evidence matrix. The
evaluation matrix included the following information for
each criterion of the framework: i) available scientificand colloquial data obtained from a literature review
supplemented by data analyses and ii) quantitative per-
formance scores of this intervention for each criterion of
the core model and qualitative impacts for each context-
ual criterion.
Participants scored the performance of the pulmonary
sensor using a scoring scale with defined anchors for
each criterion ranging from 0 to 3, except for the
intervention outcomes criteria (I1 ‘Effectiveness’, I2
‘Tolerability and Safety, I3 ‘Patient-reported outcomes’)
which also had a negative scale (−3 to +3) to capture
worse outcomes. An additional box for every criterion
was available for participants to indicate if the data was
not sufficient to understand the performance of the
sensor, which corresponded to a zero score (e.g., no
value for the sensor derived from this criterion). For
qualitative contextual criteria, participants indicated
whether consideration of a given criterion had a positive,
neutral, or negative influence on the decision about the
sensor. The estimated value of the heart sensor was
elicited by the performance scores.
The online survey was tested in advance by six partici-
pants to ensure optimal responses and understanding of
the process and of the criteria to be considered.
MCDA evidence matrix for the heart sensor
CardioMEMS, the assessed pulmonary heart sensor,
enables the permanent surveillance of patients with
chronic heart failure (New York Heart Association III),
based on telemonitoring, using a microelectromechani-
cal system. This intervention was selected as a relevant
case study given the current developments and the need
to guide future research and development in the field of
cardiology and telemedicine [27]. The implementation of
this device comes along with a change in healthcare
processes and thus affects all involved stakeholders
including patients and physicians.
The MCDA evidence matrix was populated with avail-
able data for each criterion identified through an exten-
sive literature review supplemented by additional
analyses due to the scarcity of data. The clinical efficacy
for the sensor was identified by searching healthcare da-
tabases, including PubMed, ScienceDirect (EMBASE),
and Scopus, as well as websites of HTA and regulatory
agencies. Since the device is relatively new, available data
was limited. The study team drafted the relevant HTA
report, which served as background for the MCDA
questionnaire. Clinical data was obtained from one high-
quality randomized controlled trial [28] and a Food and
Drug Administration report about the trial [29]. One
randomized clinical trial of an implantable right ven-
tricular pressure monitoring system [30] and four obser-
vational studies of implantable systems [31-34] were also
identified. The studies’ outcomes indicated reduced
Table 1 Participant characteristics
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the use of the pulmonary heart sensor. However, these
trials assess different device systems [31,33,34]. It can be
deduced that medical devices from the same group can
radically change the outcome. Data about epidemiology
of heart failure (incidence, mortality, etc.) in Germany
was obtained from the Federal Statistical Office and sev-
eral academic publications [35-39]. The current treat-
ment standards for heart failure were obtained from
national and international clinical guidelines [40-42].
Economic data on the device was estimated based on
epidemiological data and treatment costs according to
the Disease Related Groups of heart failure in Germany.
Study participants
In total, 100 stakeholder representatives were contacted
by email to participate in the survey (20 from each
group) with an emailed invitation letter describing the
project. The five key responder groups represented key
healthcare stakeholders including health professionals,
health policymakers, including from the Federal Joint
Committee (GBA), Institute for Quality and Efficiency
in Health Care, Statutory Health Insurance (GKV-
Spitzenverband), industry, citizens, and researchers.
Participants were identified through personal and business
networks of the research group and were asked to take
their own perspective into account when providing the
relative importance of decision criteria and appraising the
selected intervention for reimbursement decisions.
Data analyses
Weights, scores, and impact obtained from the partici-
pations were analyzed in Excel. Descriptive statistics
were applied and mean and standard deviations (SD)
calculated in Excel. Normalized weights and scores were
combined for each criterion (thus representing the con-
tribution of each criterion to the value estimate) and
summed using a linear additive model to calculate the
MCDA value estimates for each participant, for each
group of stakeholders, and for all participants [23].
Descriptive statistics (mean scores, SDs) are reported
for those criteria for which largest differences across
groups were observed. The cut-off value for reporting
differences between mean for stakeholders and the mean
for the whole population were set at 0.008 for normal-
ized weights (distributed to sum up to 1) and 0.2 differ-
ence for scores (on a scale of 0 to 1).
Results
Participants
In total, 54 participants completed the survey (54% re-
sponse rate) as illustrated in Table 1. From these partici-
pants, 70% (38 participants) completed the second part
of the survey regarding appraisal of the healthcareintervention. The surveyed population included stake-
holders across the healthcare sector, comprised of by
health professionals (13%), policymakers (16.7%), indus-
try representatives (18.5%), citizens (20.4%), and health-
care researchers (31.5%).
Perspectives and preferences of stakeholders on decision
criteria
Regarding relative weights provided by survey partici-
pants, Figure 1 shows that the most important criteria
(normalized across criteria to sum up to 1) were
‘Improvements of efficacy/effectiveness’ (mean relative
weight 0.086 [SD, 0.0125]), ‘Improvements in patient
reported outcomes’ (0.082 [SD, 0.013]), ‘Disease severity’
(0.080 [SD, 0.016]), ‘Improvement in safety and tolerabil-
ity’ (0.076 [SD, 0.015]), and ‘Relevance and validity of
evidence’ (0.076 [SD, 0.014]). Least important criteria
were ‘Budget impact on health plan’ (0.057 [SD, 0.021]),
‘Impact on other spending’ (0.061 [SD, 0.021]), and ‘Size
of population’ (0.063 [SD, 0.024].
The largest variations in weights across participants
were observed for ‘Size of population’ (SD, 0.024) and
the criteria ‘Type of medical service’ (SD, 0.021), ‘Budget
impact’ (SD, 0.021), and ‘Impact on other spending’ (SD,
0.021). The smallest variations were observed for
‘Improvements in effectiveness/efficiency’ (SD, 0.012)
and the criteria ‘Public health interest’, ‘Improvement in
patient-reported outcomes’, and ‘Completeness and
consistency of the reported evidence’ (all SD, 0.013).
Regarding differences in weights between stakeholder
groups, policymakers weighted the criteria ‘Budget
impact’ and ‘Relevance and validity of evidence’ higher
(+0.013 and +0.008, respectively) compared to all partic-
ipants; they reported a lower relative weight for ‘Type of
medical service’ (−0.011) and ‘Severity of disease’
(−0.008) (Additional file 2: Figure S1). From the perspec-
tive of health professionals, economic criteria were less
important than for all participants, particularly ‘Budget
impact’ (−0.018) and ‘Cost-effectiveness’ (−0.008); they
also weighted the ‘Size of the affected population’ lower
(−0.010) and the criterion ‘Limitations of comparable
interventions’ higher (+0.014). Industry representatives
put more weight on the ‘Cost-effectiveness of an inter-
vention’ (+0.008) compared to all participants.
Figure 1 Relative weights for each criteria of the MCDA Core Model for all study participants. A 5-point weight elicitation technique was used
(1 = low importance; 5 = high importance). The standard deviation of individual values and weights were normalized to sum up to 1.
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Table 2, a majority of respondents indicated that criteria
‘Goal of healthcare’ (92.45% responding often or always),
‘Fairness and priorities’, ‘Opportunity costs and feasibil-
ity’, ‘System capacity’, and ‘Regulatory status’ should be
considered often or always when making reimbursement
decision on healthcare interventions. In contrast, a major-
ity of respondents indicated that ‘political and historical
context’ (35.84% for never or rarely) and ‘Pressures/
barriers from stakeholders’ (60.38% for never or rarely)
should never or rarely be considered in decision-making.
Appraisal of the medical technology
The quantitative appraisal revealed that the highest per-
formance scores for the sensor outlined in Figure 2 were
for the criteria ‘Size of the affected population’ (0.90 on
a scale of 0 to 1 [SD, 0.3]), ‘Severity of disease’ (0.77 [SD,
0.3]), ‘Comparative intervention limitations’ (0.71 [SD,
0.4]), and ‘Improvement of efficacy/effectiveness’ (0.71
[SD, 0.34]). Lowest performance scores were observed
for ‘Improvement of safety and tolerability’ (0.19 [SD,Table 2 Participant responses to whether contextual criteria s
interventions (% of respondents)
Never
Et1 Utility – Goals of healthcare system/plan 0.0%
Et2 Fairness – Priorities and access of healthcare system 1.9%
Et3 Opportunity costs and affordability 0.0%
O1 System capacity and requirements 3.8%
O2 Political and historical context 15.1%
O3 Pressures/barriers from stakeholders 26.4%
O4 Environmental impact 3.8%
O5 Regulatory status 3.8%0.53]), ‘Public health interest’ (0.21 [SD, 0.26]), and ‘Rele-
vance and validity of evidence’ (0.25 [SD, 0.24]).
Consensus across participants on the performance
scores for the sensor were most likely to be observed for
‘Size of population’ (SD, 0.2) and ‘Impact on other
spending’ (SD, 0.2). The largest variations in scores
across all stakeholders were observed for the criteria
‘Improvements in safety and tolerability’ (SD, 0.5)
and ‘Clinical guidelines’, ‘Budget impact’, and ‘Cost-
effectiveness’ (all SD, 0.4).
These results were also reflected in the MCDA value
estimate of 0.48 (on a scale of 0 to 1 or 48% of max-
imum value; Figure 3), obtained by combining normal-
ized weights and performance scores. Major value
contributors were the criteria ‘Severity of disease’ (0.19;
SD, 0.07), ‘Size of affected population’ (0.17; SD, 0.06),
‘Comparative intervention limitations’ (0.17; SD, 0.07),
and the ‘Improvement of efficacy/effectiveness’ (0.18;
SD, 0.09).
Although statistical comparisons across stakeholder
groups could not be performed due to a small samplehould be considered in coverage decisions on healthcare
Rarely Sometimes Often Always
0.0% 7.6% 37.7% 54.7%
1.9% 15.1% 50.9% 30.2%
3.8% 15.1% 56.6% 24.5%
5.7% 30.2% 43.4% 17%
20.8% 45.3% 15.1% 3.8%
34% 32.1% 7.5% 0.0%
17% 45.3% 17% 17%
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D1   Disease severity
D2   Size of population affected by disease
C1   Clinical guidelines
C2   Comparative interventions limitations
I1   Improvement of efficacy/effectiveness
I2   Improvement of safety & tolerability
I3   Improvement of patient reported outcomes
T1   Public health interest
T2   Type of medical service
E1   Budget impact on health plan
E2   Cost-effectiveness of intervention
E3   Impact on other spending
Q2   Completeness and consistency of reporting…
Q3   Relevance and validity of evidence
Figure 2 Performance scores of CardioMEMS for each criteria of the MCDA Core Model. Scoring scales of 0 to 3 were used for all criteria except −3 to +3
for clinical criteria (I1, I2, I3). These scores and the standard deviation of individual values were transformed to a scale of 0 to 1.
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Figure S2B). Health professionals and academic re-
searchers provided a lower score for the performance of
the sensor on the criteria ‘Comparative intervention lim-
itations’ (−0.2) compared to all participants. Health pro-
fessionals scored ‘Improvement of efficacy/effectiveness’
for the heart sensor higher (+0.2) compared to all partic-
ipants. The performance scores of the industry group
were markedly higher for several criteria, particularly cri-
teria of the clusters ‘Context of intervention’ (C1: +0.2,
C2: +0.2), ‘Intervention outcomes’ (I1: +0.2, I2: +0.2,
I3: +0.2), and ‘Budget impact’ (+0.4). Health policy-
makers provided lower scores compared to all participants,
which was particularly marked for ‘Improvement of
efficacy/effectiveness’ (−0.2) and ‘Cost-effectiveness’ (−0.3).
On the other hand, the scores of the industry group were
markedly higher for several criteria, particularly criteria of-0.10
D1   Disease severity
D2   Size of population affected by disease
C1   Clinical guidelines
C2   Comparative interventions limitations
I1   Improvement of efficacy/effectiveness
I2   Improvement of safety & tolerability
I3   Improvement of patient reported outcomes
T1   Public health interest
T2   Type of medical service
E1   Budget impact on health plan
E2   Cost-effectiveness of intervention
E3   Impact on other spending
Q2   Completeness and consistency of reporting…
Q3   Relevance and validity of evidence
% of maximum value estimate
Figure 3 Value estimate of CardioMEMS and contribution of each criterion
contribution of each criterion were normalized to sum up to 1.the clusters ‘Context of intervention’ (Disease severity: +0.2,
Size of population: +0.2), ‘Intervention outcomes’ (Improve-
ment of efficacy: +0.2, Improvement of safety: +0.2,
Improvement of PRO: +0.2), and ‘Budget impact’ (+0.4).
These variations resulted in the highest value estimate of
the sensor of 0.68 (on a scale of 0 to 1, 1 representing max-
imum value) for the industry group and lowest estimate of
0.40 for policymakers, compared to 0.48 for all participants.
Regarding qualitative contextual criteria, as illustrated in
Figure 4, a majority of respondents agreed on the utility of
the sensor (prevention of hospital stay) for the healthcare
system, and thus its alignment with the goals of the health-
care system, as illustrated by a positive impact of consider-
ation of the criterion on the quantitative value assessment.
Consideration of environmental criteria had a positive im-
pact on its value due to its degradability as it works with-
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Et1  Utility - Goals of healthcare system/plan
Et2  Fairness - Priorities and access of healthcare
system
Et3  Opportunity costs and affordability
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O4  Environmental impact
Negative Impact Positive Impact No  Impact
Figure 4 Impact of contextual criteria about CardioMEMS (sum of votes for positive (1), negative (−1), or neutral (0) impact).
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value of the sensor. Divergences were observed on the im-
pact of considering opportunity costs and affordability on
the overall value of the sensor.
Discussion
This study identified issues about current perspectives
on HTA in the German context as well as important
variations across German stakeholders when appraising
healthcare interventions. EVIDEM, as a decision support
tool, was not directly designed to assess perspectives.
Still, the perspectives of stakeholders translate into judg-
ments at the criteria level. EVIDEM allowed exploration
of these judgments with regards to two aspects: i) indi-
vidual preferences and values on what matters most, or
in other words, which criteria contribute the most to the
worth of healthcare interventions in general (captured
by weights independently of the intervention), and ii)
understanding the value of a heart sensor measured by
the contribution of a comprehensive range of criteria
(elicited by performance scores).
Firstly, values and preferences provided the base for
statements about the relative importance of assessment
criteria. Other MCDA studies used DCEs to elicit prefer-
ences [14,15,17,20]. This is an issue which is also cur-
rently considered by the MCDA in Health Care Decision
Making Emerging Good Practices Task Force of the
ISPOR society. They recommend stated preference
methods that “are used to weight decision criteria” [43].
Consequently, criteria weights can be regarded as
preferences.
Secondly, stakeholders need to perceive and under-
stand the complex evidence about health technologies,
i.e., CardioMEMS. However, the perception and under-
standing of the provided evidence can be very different
depending on the professional background of each stake-
holder. As highlighted in our study, stakeholders scored
the evidence very differently, depending on theirpersonal background. Finally, the qualitative feedback
contains both aspects: preferences and values as well as
perception and understanding of the evidence.
Better understanding of these differences across stake-
holders at the criteria level is important to focus innovation
aligned with patient health and healthcare system values
and constraints [44].Perspectives and preferences of stakeholders on decision
criteria
Participants representing all types of stakeholders across
the healthcare decision continuum in Germany indicated
that the most important criteria for reimbursement deci-
sion making were ‘Improvement of efficacy/effectiveness’,
‘Improvements in patient reported outcomes’, ‘Disease
severity’, ‘Improvement in safety’, and ‘Quality of evidence’
(relative weight >0.075 each). These results are to some
extent in agreement with results of an international survey
of decision criteria which indicated that most important
decision criteria included ‘Clinical efficacy’, ‘Safety’, ‘Quality
of evidence’, ‘Disease severity’, and ‘Impact on healthcare
costs’ [45], a major difference being the importance of cost
consideration.
This survey reveals the primary importance to German
stakeholders related to the three criteria of the cluster
‘Intervention outcomes’, including ‘Improvement in effi-
cacy/effectiveness’, ‘Improvement in safety’, and ‘Im-
provement in patient reported outcomes’, as well as the
consensus on this point, revealed by the lowest SD
across participants on their relative importance. This is
in agreement with the current HTA approach in place in
Germany through the GBA, which gives a high import-
ance to ‘Incremental efficacy’, ‘Incremental safety’, and
‘Incremental patient reported outcomes’. Indeed, patient
relevant outcomes (mortality, morbidity, and health-
related quality of life) are the only criteria used in the
assessment of the benefit of medical interventions [46].
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third in this survey, revealing the importance of one of
the fundamental objectives of healthcare to alleviate suf-
fering in those who are worst off. However, current
health policy does not actively take severity of disease
into account [47]. The level of incremental benefit of a
given healthcare intervention (defined as substantial, ap-
preciable, moderate, present but not quantifiable, no
benefit, or negative benefit) is determined by the GBA
through a process that mentions that disease severity is
considered, but it is not clearly stated how this is done
[48]. Although stakeholder groups were too small to per-
form comparative statistical tests, the criterion ‘Disease
severity’ appeared to be less important to policymakers
compared to all participants, possibly pointing to a dis-
crepancy between policies and the ethical implications
associated with the concept of severity of diseases.
For policymakers, the criterion ‘Quality of the evi-
dence’ was more important than for other stakeholders,
revealing the value of evidence based decision-making in
the German context. The GBA emphasizes the quality of
evidence which needs to clearly demonstrate any
claimed benefit [48].
For all participants, weights for economic criteria were
generally lower than for other clusters of criteria, and
‘Budget impact of the intervention’ had the lowest
weight of all criteria. Still, the highest SD (0.024) across
all criteria indicated a poor agreement on the import-
ance of economic issues. Across groups of stakeholders,
the lowest weights on economic criteria were observed
from the responses of health professionals, which reveal
their wish to help patients without focusing on eco-
nomic constrains [49-51]. These results are in line with
currently implemented decision-making processes in
Germany and the values associated with the process
[52]. The German decision-making body (the GBA) as-
sesses the incremental benefit of a new intervention with
respect to an appropriate comparator. After a positive
assessment, the economic aspects are considered taking
the clinical benefit of the new intervention into account.
Regarding the qualitative assessment, a majority of
stakeholders reported that criteria alignment of interven-
tions with the ‘Goal of healthcare’, ‘Fairness and priorities’,
‘Opportunity costs and feasibility’, ‘System capacity and
implementation’, and ‘Regulatory status’ should be consid-
ered in reimbursement processes. These qualitative but
sometimes critical elements of decisions need a more for-
mal integration into existing processes. Regarding the cri-
teria ‘Political and historical context’ and ‘Pressures/
barriers from stakeholders’, full awareness of these aspects
may be critical to make provisions to ensure acceptability
and implementation of decisions [53,54], although a ma-
jority of participants indicated that these should not play a
role in reimbursement decision making.Appraisal of the medical technology
Appraisal of the pulmonary heart sensor revealed that
the major contributors to the value of this innovation
were ‘Size of population’, ‘Severity of disease’, and ‘Com-
parative intervention limitations’, highlighting the health
need for the management of heart failure. ‘Improvement
in efficacy/effectiveness’ was also a major contributor
but limited data (one randomized controlled trial of
6 months duration) [28] was criticized as not being suffi-
cient for informed decision-making. The quantitative ap-
praisal of the pulmonary heart sensor revealed large
differences in performance scores across participants for
many criteria, with the largest SD in scores observed for
the criteria ‘Improvements in safety and tolerability’ (SD,
0.5), ‘Clinical guidelines’, and ‘Cost-effectiveness’ (both
SD, 0.4). These variations may stem from different per-
spectives across participants, but given data limitations,
and the fact that a survey format does not allow for dis-
cussion, uncertainty and/or misinterpretation might also
have contributed to these large variations. Such differ-
ences in scoring were not observed in other settings in
which the EVIDEM framework was applied to assess in-
terventions by standing committees, and during which
discussion and group interpretation of data took place
before or during scoring [24,25].
Although stakeholder groups were too small to per-
form comparative statistical tests, a quantitative ap-
praisal of the pulmonary heart sensor revealed large
differences in scores between stakeholder groups. Health
professionals scored ‘Improvement of efficacy/effective-
ness’ for the heart sensor higher (+0.2 compared to all
participants) while health policymakers scored this cri-
teria lower (−0.2 compared to all participants). This sug-
gests a more stringent judgment on what constitutes an
improvement from health policymakers. The scoring
scales of the MCDA framework used in the survey
capture the judgment made on evidence, which results
from an objective interpretation of evidence and a more
subjective definition of what constitutes a major, moder-
ate, minor, absence of improvement, or worsening of
efficacy/effectiveness. Despite the caveats discussed
above, this difference appears to quantitatively confirm
the different viewpoints on the value of new interventions
between innovation-oriented manufacturers and policy-
makers and purchasers of innovation in Germany [55].
This value estimate of 48% is of interest as far as it
represents the contribution of each criterion to value,
but the absolute value has limited interest in the absence
of a frame of reference. Comparisons to other MCDA
studies are not appropriate due to different sets of deci-
sion criteria and the application of other technical ap-
proaches, e.g., AHP. The comparison to other EVIDEM
studies concludes certain reliability across different cul-
tural, societal, and economic settings. MCDA estimates
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tients [23], 44% for Tramadol for chronic non-cancer
pain [25], and 42 to 64% for 10 medicine appraisals in
Canada [22]. Additionally, there is a 46% for coverage of
a screening test for cervical cancer in South Africa [24].
However, it is not appropriate to compare the final esti-
mates for several reasons. The criteria received different
weights and the healthcare system and the cultural per-
spective differed from the German setting. Importantly,
to the best of our knowledge, this is the first MCDA
study using the EVIDEM 2.2 tool. Within this tool,
scores can also be negative, e.g., if the intervention is less
effective than the comparator. This factor contributes to
a lower estimate value. For interpretation of the calcu-
lated value estimates, a comparison needs to be under-
taken with other interventions in a second survey. When
several interventions are appraised with such approaches
by the same committee, as is the case in the HTA
agency for the Lombardy region, where more than 20 in-
terventions have been assessed with the MCDA ap-
proach, with a range of value estimates ranging between
0.22 and 0.72 (Michele Tringali, personal communica-
tion), such approaches are useful to rank interventions
and guide decision-making at the system level.
As recommended by Baltussen et al. [56], MCDA esti-
mates should be used as a guide to decision-making, ra-
ther than as a formula. This study revealed positive and
negative impacts of qualitative criteria on the overall
MCDA estimate. For example, by prompting participants
to consider the environmental criteria, some element of
value for the sensor could be captured qualitatively due
to its degradability as it works without chemical batter-
ies. Without a holistic framework, such considerations
are unlikely to be brought to the discussion in line with
results of an international survey which demonstrated that
30% of decision-makers currently consider environmental
consequences of healthcare interventions but 70% indi-
cated that it should be considered systematically [45].
Limitations of the study
Study results should be considered in light of their limi-
tations. We selected the 5-point weight elicitation tech-
nique and used linear scoring scales to keep the survey
simple and to shorten time commitment. Still, it would
be of interest to explore other weighting techniques and
different types of scales as a follow-up to this explora-
tory study. In particular, the fact that differences in
criteria weights had only limited influence on the overall
value estimates raises some questions. The discrimin-
atory power of the 5-point scale might be limited regard-
ing the large number of criteria. As this was the first
application of the EVIDEM framework to explore differ-
ences in criteria weights across stakeholder groups, this
limitation should be taken into account for furtherresearch. Preston et al. [57] highlighted that scales with
more categories (i.e., 7, 9, or 10) are most appropriate
for most survey projects.
Our sampling approach (identification of participants
through personal contact) has to be taken into account
carefully when interpreting the presented results. How-
ever, this systematic sampling approach ensured a high
response rate of 54%. Comparisons across groups of
stakeholders are exploratory given the small sample size
and the stochastic nature of the data, but nonetheless
revealed differences. The lack of appropriate evidence,
for most criteria, and difficulties in understanding the
complex information resulted in lower scores and higher
SDs, reflecting uncertainty on data and limitations in
appraisal. Lay participants felt overtaxed by scientific
evidence which is also true for patient representatives in
other studies [17]. For stakeholders not working directly
in a scientific field related to healthcare, graphical pres-
entation and the teaching of basic statistical approaches
can support the understanding of the provided informa-
tion [58,59]. Despite the committee setting, these
limitations can be partially overcome by discussion and
input from experts for each criteria in order to facilitate
interpretation of data; data limitations are a common
issue in appraisals of health technologies [60].
Conclusions
This study provided important insights into the current
decision-making landscape in Germany and revealed
that MCDA can demonstrate the value of a specified
technology for all participating stakeholders. The appli-
cation of a multi-criteria framework allowed to identify
perspectives across German stakeholders when apprais-
ing a healthcare intervention at the criteria level, both
quantitatively and qualitatively. A better understanding
of these differences at the criteria level, in particular
between policymakers and industry representatives, is
important to focus innovations aligned with healthcare
system values and constraints. The appraisal of the pul-
monary heart sensor highlighted the health need for the
management of heart failure. Multi-criteria frameworks
provide a basis of dialogue between all stakeholders,
which is beneficial for all parties [61], and which allows
the definition of the most valuable interventions for
patient and population health that can also contribute to
sustainable, efficient, and equitable healthcare systems,
thus facilitating access to patients [62,63]. By combining
the benefits of both simple heuristic judgments (e.g.,
trade-offs) [64] and structured mathematical models
[65], multi-criteria supports the complexity of evalua-
tions and decision-making and provides a mean to eluci-
date and discuss variations in perspectives across
stakeholders at the criteria level. Further research is
needed to explore the role of multiple criteria to develop
Wahlster et al. Health Research Policy and Systems  (2015) 13:24 Page 10 of 11fair and accountable processes based on a better under-
standing of perspectives across the healthcare decision
continuum within a society and across cultures. Such
approaches can also provide some powerful analytical
tools to identify how social values affect decision-
making [66].
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